Samantha Du's Zai Lab sets its ambitions sky high, looking to raise $750M to fuel its licensing business model
Looking to capitalize on a bustling Chinese drug market, upstart biotechs like Samantha Du’s Zai Lab have made a killing in-licensing foreign molecules as well as developing their own homegrown assets. Now, with even more growth in mind, Zai Lab has offered up a healthy chunk of shares on the US market to fuel its ambitions.
Zai Lab will offer $750 million in US depository shares as part of a major cash raise to keep driving its in-licensing business engine as well as advance its suite of clinical programs, the Chinese biotech said this week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.